pharma · Interstitial Lung Disease (ILD) · Gastrointestinal Disease
ZhongShan Hospital, Fudan
Shanghai Zhongshan Hospital
Shanghai Zhongshan Hospital is a pharma organization headquartered in CN. Primary therapeutic focus areas include Interstitial Lung Disease (ILD), Gastrointestinal Disease, Takayasu Arteritis. NovaPharmaNews links 3 clin
CN HQ
1936 Founded
624 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- CN
- Founded
- 1936
- Employees
- 624
- Programs
- 3
- Drugs
- 8
- Patents
- 0
Tocilizumab
Approved · mab · Takayasu Arteritis
Tocilizumab for Takayasu Arteritis is a Approved program (mab) at Shanghai Zhongshan Hospital with 1 ClinicalTrials.gov record(s).
Internal code TACTIC-SS
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Shanghai Zhongshan Hospital
- Phase
- Approved
- Modality
- mab
- Indication
- Takayasu Arteritis
- Status
- active
- Trials
- 1